From January to November 2025, veterinary pharmacies and pet stores in Russia sold 257.1 million minimum dosing units (MDUs) of veterinary medicines. Over the year, physical consumption increased by 13.4%. At the same time, total spending on this assortment rose by 16.9% compared with January–November 2024 and, by the end of the first eleven months of 2025, reached RUB 45.6 billion (at retail prices, including VAT).

According to data from the RNC Pharma database Audit of Retail Sales of Veterinary Medicines in Russia (total sell out), a pronounced peak in sales of veterinary medicines is traditionally recorded in the spring. Notably, throughout 2025, starting from March, physical consumption of veterinary medicines remained at a consistently high level: Russian consumers purchased an average of about 24 million MDUs per month, which markedly differs from trends observed in previous years. The gradual increase in consumption during traditionally “low” seasons is associated with the introduction over recent years of new products, for which peak demand also occurs during the summer period.

It should be emphasized that sustained demand for veterinary medicines throughout 2025 was largely driven by a significant increase in sales of domestically produced products. Compared with January–November 2024, sales of Russian veterinary medicines rose by 36% in value terms and by 26% in physical terms. At the same time, the assortment of domestic products expanded by 166 SKUs (stock keeping units—product item identifiers), reaching a total of 3.4 thousand items. In contrast, the number of product positions of foreign-origin veterinary medicines declined by 65 SKUs; over the first eleven months of 2025, sales were recorded for approximately 2.3 thousand such items. During the reporting period, veterinary medicines produced by foreign companies also showed a significant decrease in physical demand (–11% in MDUs), while value sales in rubles declined slightly as well (–0.8%). As a result, the physical share of domestic products on the retail veterinary medicines market exceeded 73% during the period, while their value share reached 56%.

Based on the results for January–November 2025, the U.S.-based company Zoetis retained leadership on the Russian retail veterinary medicines market, with a 12.3% value share. The second position was held by the Russian company Ecoprom (10.4% in value terms), while third place belonged to Slovenia’s KRKA (10%). It is important to note changes in the Top 10 corporations over the past year: against the backdrop of declining shares for some foreign companies, another Russian manufacturer, Vetbiokhim, entered the leading ten. Compared with January–November 2024, sales of this company’s products doubled. Growth was primarily driven by vaccines for the preventive immunization of companion animals, such as Multikan, Multifel, and Asterion, sales of which increased by two to three times over the year.

The most dynamic value growth among Top 20 market players during the analyzed period was demonstrated by the Russian company Vetpharmstandard. In the second half of 2024, the company launched the insectoacaricidal product Tixfly, which rapidly entered the Top 10 most popular veterinary medicines of the past year. As of now, the manufacturer ranks 13th in the corporate ranking.

Figure. Dynamics of veterinary medicine sales on the Russian retail market, January 2024 – November 2025